The place of sulphonylurea based insulin secretagogues in the management of T2DM is as controversial today as it was fifty years ago. Sulphonylureas play an important role in management of people with type 2 diabetes. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. In this webinar we discuss the role and relevance of low dose sulphonylureas in the management of T2DM.
Dr. Sanjay Kalra
DM (AIIMS) President-elect, SAFES Bharti Hospital, Karnal, India
